Enveric Biosciences, Inc.
ENVBHealthcare|Biotechnology|US
$1.42
+0.00 (+0.28%)
DCF Value
$12.40
Tangible Book / Share
$2.03
Cash / Share
$2.08
About
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Stock Price
-76.5%(1Y)
1M
-6.3%
3M
-8.1%
6M
-50.0%
YTD
-60.8%
1Y
-75.4%
3Y
-99.6%
5Y
-100.0%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$6.4M
Employees5 (+0% YoY)
CEOJoseph Edward Tucker
IPO DateMay 4, 2015
Beta1.21
52-Week Range$1.17 – $13.25
Avg Volume88,856
ExchangeNASDAQ
Websiteenveric.com
Ownership
Float98.4%
Shares Outstanding4.5M
Recent Insider Trades
DeWitt SheilaAWARD
Dec 23, 20257,633 shares
Kegler George A.AWARD
Dec 23, 20257,633 shares
PASQUALONE FRANKAWARD
Dec 23, 20257,633 shares
Schabacker MarcusAWARD
Dec 23, 20257,633 shares
Tucker Joseph EdwardAWARD
Dec 23, 202560,296 shares
Peers
Recent News
Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study
Nov 4, 2026 · businesswire.com
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
Oct 21, 2026 · businesswire.com
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Sep 15, 2026 · businesswire.com
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
Sep 1, 2026 · businesswire.com
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
Aug 14, 2026 · businesswire.com
Data last updated: Nov 9, 2026, 04:09 AM